BOTANIX PHARMACEUTICALS LTD — Director's Dealing 2022

Jul 7, 2022

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Botanix Pharmaceuticals Limited ABN 70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Vincent Ippolito
Date of last notice	01/07/20

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest	Mr Ippolito is a trustee of the Ippolito Trust
(including registered holder)
Note: Provide details of the circumstances
giving rise to the relevant interest.
Date of change	07/07/2022
No. of securities held prior to change
Vincent Peter Ippolito	12,000,000 Unlisted Options exercisable at $0.251 expiring 18
	July 2023
Vincent Peter Ippolito	17,994,914Unlisted Options exercisable at 0.0551 each, expiring
	30 June 2022
Vincent Peter Ippolito and Karen	3,000,000 Unlisted Options exercisable at $0.115 expiring 23
Ann Ippolito <The Ippolito	May 2023
Trust>
Class	Ordinary Shares
	Unlisted Options
Number acquired	5,286,493 Ordinary Shares
Number disposed	17,994,914 Unlisted Options

Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation	$0.0551 per share
No. of securities held after the changeVincent Peter IppolitoVincent Peter Ippolito and KarenAnn Ippolito <The IppolitoTrust>	5,286,493 Ordinary Shares12,000,000 Unlisted Options exercisable at $0.251 expiring 18July 20233,000,000 Unlisted Options exercisable at $0.115 expiring 23May 2023
Nature of changeExample: on-market trade, off-market trade,exercise of options, issue of securities underdividend reinvestment plan, participation inbuy-back	Exercise of Unlisted Options utilising cashless exercise facility

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

thispart.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide detailsand an estimated valuation	N/A
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed abovetraded during a+closed period where prior written clearancewas required?	No
If so, was prior written clearance provided to allow the trade toproceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Botanix Pharmaceuticals Limited
ABN	70 009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr H. William Bosch
Date of last notice	01/07/2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstancesgiving rise to the relevant interest.
Date of change	07/07/2022
No. of securities held prior to change	16,000,000 Ordinary Shares4,863,490 Unlisted Options exercisable at 0.0551 each, expiring30 June 2022
Class	Ordinary SharesUnlisted Options
Number acquired	321,551 Ordinary Shares
Number disposed	4,863,490 Unlisted Options
Value/ConsiderationNote: If consideration is non-cash, providedetails and estimated valuation	$0.0551per share
No. of securities held after change	16,321,551 Ordinary Shares

Nature of change Exercise of Unlisted Options utilising cashless exercise facility Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back

Part 2 – Change of director’s interests in contracts – N/A

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

thispart.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

art 3 –+Closed period
Were the interests in the securities or contracts detailed above	No
traded during a+closed period where prior written clearance
was required?
If so, was prior written clearance provided to allow the trade to	N/A
proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001.

	Name of entity Botanix Pharmaceuticals Limited
	ACN009 109 755

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Stewart Washer
Date of last notice	22/02/2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to therelevant interest.	Dr Stewart James Washer & Dr PatriziaDerna Washer as trustee for the WasherFamily Trust(Dr Washer is a trustee and beneficiary of thetrust)
Date of change	21/02/2022
No. of securities held prior to change
Dr Stewart James Washer & Dr Patrizia DernaWasher as trustee for the Washer Family Trust	4,863,490 Unlisted Options exercisable at0.0551 each, expiring 30 June 2022
Class	Ordinary SharesUnlisted options
Number acquired	321,551 Ordinary Shares
Number disposed	4,863,490 Unlisted Options
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$0.0551 per share

• See chapter 19 for defined terms.

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

	AppendiChange of Director’s Interest N
No. of securities held after changeDr Stewart James Washer & Dr Patrizia DernaWasher as trustee for the Washer Family Trust	321,551 Ordinary Shares
Nature of changeExample: on-market trade, off-market trade, exercise of options,issue of securities under dividend reinvestment plan, participationin buy-back	Exercise of Unlisted Options utilisingcashless exercise facility

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract in relation to which theinterest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, provide details and an estimatedvaluation	N/A
Interest after change	N/A

Part 3 Closed Period

Part 3 Closed Period
Were the interests in the securities or contractsdetailed above traded during a +closed periodwhere prior written clearance was required?	No
If so, was prior written clearance provided toallow the trade to proceed duringthis period?	N/A
If prior written clearance was provided, on whatdate was this provided?	N/A

• See chapter 19 for defined terms.

Appendix

3Y

2

Page